Owner Scorecard


← All companies ← RGA Manual RGLD → ← QGEN Biotechnology RGNX →

RGEN, Repligen Corporation

Biotechnology consumer brand Serial acquirer

Repligen is a global life sciences company that develops and commercializes highly innovated bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

As the overall market for biologics continues to grow and expand, our customers primarily large biopharmaceutical companies and contract development and manufacturing organizations ("CDMOs") and other life sciences companies (integrators) face critical production cost, capacity, quality and time pressures.

Our products help enable customers to address these concerns, both accelerating development and improving yields.

Latest annual: FY2025 10-K
RGEN · Repligen Corporation
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$738M
+16.4% YoY · 15% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $763M 5-yr avg $695M
Gross margin 53% 5-yr avg 51%
Operating margin 8.5% 5-yr avg 12.5%
ROIC 3% 5-yr avg 6%
Owner-earnings margin 14% 5-yr avg 15%
Free cash flow margin 14% 5-yr avg 13%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is led by Filtration Products (55%) and Chromatography Products (21%), with 2 more lines behind.
Situation
Serial acquirer. Goodwill and acquired intangibles are 51% of assets, with meaningful acquisition spending in 8 of the record's 10 years; much of what this business is was bought, at prices the record carries.
What moves the needle
Gross margin has run about 55% and operating margin about 13% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −5.5% to 28% over the years — so the through-cycle figure carries more than any single year, and the worst year more than the best. Inventory runs near 24% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median 4%, above 15% in 0 of 10 years). By owner earnings: roughly 12% of revenue reaches owners as cash, consistently. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

Revenue spreads across 6 lines, the largest Filtration Products at 55%.

Revenue by product line, FY2025
  • Filtration Products55%$403M
  • Chromatography Products21%$153M
  • Proteins Products13%$97M
  • Process Analytics Products11%$81M
  • Other products0%$3M
  • Royalty0%$296K

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$105M$141M$194M$270M$366M$671M$802M$632M$634M$738M$763MRevenueRevenue
55%53%55%56%57%58%57%44%43%52%53%Gross marginGross mgn
30%36%34%35%33%27%27%35%42%39%39%SG&A / revenueSG&A/rev
7%6%8%7%6%5%5%7%7%7%7%R&D / revenueR&D/rev
$16M$14M$26M$36M$70M$167M$225M$48M($35M)$55M$65MOperating incomeOp. inc.
15.3%9.9%13.4%13.4%19.1%24.9%28.0%7.5%−5.5%7.5%8.5%Operating marginOp. mgn
$12M$28M$17M$21M$60M$128M$186M$36M($26M)$49M$51MNet incomeNet inc.
0%22%18%-1%16%15%37%22%9%Effective tax rateTax rate
Cash flow & returns
$8M$17M$33M$67M$63M$119M$172M$114M$175M$117M$131MOperating cash flowOp. cash
$5M$11M$16M$21M$27M$38M$51M$69M$70M$79M$80MDepreciationDeprec.
($14M)($28M)($10M)$12M($41M)($75M)($92M)($16M)$83M($43M)($34M)Working capital & otherWC & other
$4M$5M$11M$19M$22M$67M$85M$36M$26M$24M$25MCapexCapex
4.1%3.9%5.5%6.8%6.1%10.0%10.6%5.7%4.0%3.2%3.2%Capex / revenueCapex/rev
$3M$12M$22M$49M$40M$81M$121M$78M$150M$94M$106MOwner earningsOwner earn.
3.1%8.5%11.4%18.0%11.0%12.0%15.1%12.3%23.6%12.7%13.9%Owner earnings marginOE mgn
$3M$12M$22M$49M$40M$52M$87M$78M$150M$94M$106MFree cash flowFCF
3.1%8.5%11.4%18.0%11.0%7.7%10.9%12.3%23.6%12.7%13.9%Free cash flow marginFCF mgn
$45M$113M$182M$175M$150M$0$187M$55M$70M$608KAcquisitionsAcquis.
$0$0$14M$0$0BuybacksBuybacks
11%3%5%4%9%12%14%2%-2%2%3%ROICROIC
7%5%3%2%4%7%10%2%-1%2%2%Return on equityROE
7%5%3%2%4%7%10%2%−1%2%2%Retained to equityRetained/eq
Balance sheet
$142M$174M$194M$528M$717M$604M$523M$751M$757M$768M$796MCash & investmentsCash+inv
$15M$28M$33M$43M$71M$117M$116M$124M$134M$159M$152MReceivablesReceiv.
$25M$39M$42M$55M$95M$184M$238M$202M$143M$170M$179MInventoryInvent.
$5M$7M$10M$11M$17M$36M$28M$20M$32M$30M$35MAccounts payablePayables
$35M$59M$65M$86M$150M$266M$327M$307M$245M$299M$296MOperating working capitalOper. WC
$184M$243M$276M$642M$902M$932M$998M$1.1B$1.1B$1.1B$1.2BCurrent assetsCur. assets
$21M$25M$130M$48M$319M$375M$404M$165M$127M$136M$126MCurrent liabilitiesCur. liab.
8.7×9.6×2.1×13.3×2.8×2.5×2.5×6.7×8.4×8.4×9.2×Current ratioCurr. ratio
$60M$327M$327M$468M$618M$860M$856M$987M$1.0B$1.1B$1.1BGoodwillGoodwill
$289M$744M$775M$1.4B$1.9B$2.4B$2.5B$2.8B$2.8B$2.9B$2.9BTotal assetsAssets
$95M$99M$0$233M$0$510M$526M$542M$547MTotal debtDebt
($47M)($75M)($194M)($296M)($523M)($241M)($232M)($225M)($250M)Net debt / (cash)Net debt
4.2×2.2×3.9×3.9×6.5×14.8×193.3×24.5×-1.7×2.6×3.0×Interest coverageInt. cov.
$169M$592M$616M$1.1B$1.5B$1.8B$1.9B$2.0B$2.0B$2.1B$2.1BShareholders’ equityEquity
4.4%4.8%5.3%4.8%4.6%4.1%3.4%4.0%7.6%4.4%4.4%Stock comp / revenueSBC/rev
Per share
34.1M39.1M45.5M49.2M53.9M57.3M57.5M56.4M55.9M56.6M56.7MShares out (diluted)Shares
$3.07$3.61$4.27$5.49$6.80$11.71$13.95$11.22$11.34$13.05$13.47Revenue / shareRev/sh
$0.34$0.72$0.37$0.44$1.11$2.24$3.24$0.63$-0.46$0.86$0.91EPS (diluted)EPS
$0.09$0.31$0.49$0.99$0.75$1.41$2.11$1.38$2.68$1.66$1.87Owner earnings / shareOE/sh
$0.09$0.31$0.49$0.99$0.75$0.91$1.52$1.38$2.68$1.66$1.87Free cash flow / shareFCF/sh
$0.13$0.14$0.23$0.38$0.42$1.17$1.48$0.64$0.46$0.42$0.44Cap. spending / shareCapex/sh
$4.95$15.11$13.54$21.54$28.37$30.56$33.26$34.85$35.27$37.24$37.16Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+17.5%/yr+13.9%/yr
Owner earnings / share+37.6%/yr+17.4%/yr
EPS+10.8%/yr−4.9%/yr
Capital spending / share+14.1%/yr−0.0%/yr
Book value / share+25.1%/yr+5.6%/yr

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
57Mpeak FY2022
ROIC
2%low FY2024
Gross margin
52%low FY2024

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

$94Mowner earningsvs.$49Mnet incomelow FY2016

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cash

Each year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.

FY2016FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned $49M of profit into $94M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

Reported net income$49M
Owner earnings$94M · 13% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$49M($26M)$36M$186M$128M
Depreciation & amortizationnon-cash charge added back+$79M+$70M+$69M+$51M+$38M
Stock-based compensationreal costnon-cash, but a real cost+$33M+$48M+$26M+$27M+$28M
Working capital & othertiming of cash in and out, other non-cash items−$43M+$83M−$16M−$92M−$75M
Cash from operations$117M$175M$114M$172M$119M
Maintenance capital expenditurethe spending needed just to hold position and volume−$24M−$26M−$36M−$51M−$38M
Owner earnings$94M$150M$78M$121M$81M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$34M−$29M
Free cash flow$94M$150M$78M$87M$52M
Owner-earnings marginowner earnings ÷ revenue13%24%12%15%12%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $33M), owner earnings is nearer $61M.

Much of fiscal 2025's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Adequate
    Operating income $55M ÷ interest expense $22M
    What this means

    Comfortable in a normal year, but below the margin of safety Graham looked for. Worth checking how stable the coverage has been across a full cycle.

  • Net cash
    Cash $566M + ST investments $202M − debt $542M
    What this means

    Cash and short-term investments exceed every dollar of debt by $225M, on net the company owes nothing, and can act from strength when others can't. It also holds $12M in longer-dated marketable securities; counting those, it sits at net cash of $238M. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 78 + DIO 177 − DPO 31 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Below average through the cycle
    10-yr median, range -2%–14%; 2% latest = NOPAT $43M ÷ invested capital $2.1B
    Industry peers: median -40%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 2% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Solid through the cycle
    10-yr median margin, range 3%–24%; latest $94M = operating cash $117M − maintenance capex $24M
    Industry peers: median -46%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 13% of revenue this year, a 12% median across 10 years. Treating stock comp as the real expense it is (less $33M of SBC) leaves $61M.

  • Cash-backed
    Cash from ops $117M ÷ net income $49M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks $0 ÷ Owner Earnings $94M
    What this means

    Of $94M Owner Earnings, $0 (0%) went back to shareholders, $0 dividends, $0 buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 0.30×
    Harvesting
    Capex $24M ÷ depreciation $79M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 6 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $738M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 8.37×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $542M vs $1.0B WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Near
    A profit every year (10-yr record) · 1 loss year
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Near
    Earnings +33% over the record · +4%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $0.35/share (latest year $0.87), the averaged base the calculator's gate runs on, and book value is $37.34/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 9 of 10
    What this means

    Lost money in 1 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 8 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 13% → 3% (3-yr avg ends)

    In the filing’s words The filing attributes gains to higher prices, but the margin in the record has not followed — the claim outruns the result here.

    What this means

    Through the cycle the operating margin slipped — about 13% early to 3% lately, median 13% — competition or costs are biting in.

  • Reinvestment, incremental ROIC −0%
    What this means

    Reinvested capital came back at a negative incremental return over this window — the invested base grew while operating profit did not. The filings show where it went.

  • Owner earnings growth +36%/yr
    What this means

    Owner earnings grew about 36% a year over the record.

  • Worst year 2024 · −5.5% op. margin
    What this means

    Operations went underwater in 2024, understand why before trusting the good years.

  • Share count +5.8%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$1.2B
  • Cash & short-term investments$785M
  • Receivables$152M
  • Inventory$179M
  • Other current assets$46M
Current liabilities$126M
  • Accounts payable$35M
  • Other current liabilities$92M
Current ratio9.20×all current assets ÷ what's due · Graham looked for 2×
Quick ratio7.78×stricter: inventory excluded
Cash ratio6.22×strictest: cash alone against what's due
Working capital$1.0Bthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+14.8%the freshest read on whether the business is still growing
Current ratio, recent quarters6.6× → 9.2×
Deeper floors
Tangible book value$630Mequity stripped of goodwill & intangibles
Net current asset value$336MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$688M$141M of it operating leases
Deferred revenue$18Mcustomer cash collected before delivery; operating float

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $885M of operating cash; how management split it reads as a cash builder, a large share of cash simply built up on the balance sheet.

  • Reinvested$299M · 34%
  • Buybacks$14M · 2%
  • Retained (debt / cash)$572M · 65%
  • Returned to owners$14M

    2% of the owner earnings the business produced over the span, $0 as dividends and $14M as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span debt rose $451M and cash and short-term investments rose $643M.

  • Average price paid for buybacks

    Buybacks ran $14M over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count66.2%

    The diluted count rose from 34M to 57M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record

    No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.

  • Return on what it retained19%

    Of the earnings it kept rather than paid out ($497M over the span), annual owner earnings (first three years vs last three) grew $95M, so each retained $1 added about 0.19 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Acquisitions & goodwill

from the balance sheet & the 10-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles$1.5B51% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equity53%goodwill is this share of book equity; the rest is the company’s own retained and paid-in capital
Cash spent acquiring$976Mover 10 years buying other businesses, against $299M of capital spent building

None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 10-year record, from the company's own filings.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Mr. Hunt$7.8M$28.8M$81M
2022$7.7M−$14.0M$121M
2022$7.7M−$14.0M$121M
2023$7.9M$8.2M$78M
2023$7.9M$8.2M$78M
2024$7.2M$5.1M$150M
2024$20.3M$921k$150M
2025Mr. Loeillot$6.1M$8.7M$94M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years. A dash under the name means the filing tags the figure without naming the officer.

  • Insider ownership0.6%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$33M

    The slice of the business handed to employees in shares this year, 4% of revenue, equal to 59% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Inverting the record

Invert: instead of why Repligen Corporation is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.

1 of the 5 tests turned up something to look into; the other 4 came back clean.

  • Look hereDid the share count rise anyway?66.2%

    Diluted shares grew 66.2% over 2016–2025, even as the company spent $14M on buybacks. The repurchases were outrun by issuance — to staff, in a raise, or in a deal — and the filing says which; owners' slice still shrank. Read the buyback line beside this one, not on its own.

And these came back clean
  • Is it less profitable than it was?
  • Did debt outgrow the business?
  • Did reported profit become cash?
  • Did receivables and inventory outpace sales?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Biotechnology

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
TECHBio-Techne$1.2B67%21.4%9%22%
NVAXNovavax Inc.$1.1B65%-117.4%-128%-50%
BCRXBioCryst Pharmaceuticals Inc.$875M95%-148.8%-142%-128%
RGENRepligen Corporation$738M55%13.4%4%12%
ADMAADMA Biologics Inc$510M-13%-106.6%-39%-158%
TARSTarsus Pharmaceuticals Inc.$451M-65.9%-41%-46%
IMCRImmunocore Holdings plc$400M99%-23.9%-3%
KRYSKrystal Biotech$389M22.6%-21%41%
Group median66%-44.9%-39%-25%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Repligen Corporation has delivered.

$

Through the cycle, Repligen Corporation earns about $90M on its 12.2% median owner-earnings margin. This year’s 12.7% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25+5%/yr
Owner-earnings growth · ’16→’25+36%/yr
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings $106M on 56M shares outstanding, per the 10-Q cover, as of 2026-05-01; net cash $250M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Repligen Corporation (RGEN), the owner's record," https://ownerscorecard.com/c/RGEN, data as of 2026-07-09.

Manual order: ← RGA its page in the Manual RGLD →

Industry order: ← QGEN the Biotechnology chapter RGNX →